Delivery Order SPE2DB24D2011-SPE2DB25FBRQC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,232.28 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 13, 2025. This competitive, firm fixed-price delivery order represents a continuation of pharmaceutical supply under AmerisourceBergen's existing contract vehicle with DLA. The award carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,254.40 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 mg/ml SureClick auto-injectors. The contract, awarded on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed price delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and serves as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors, valued at $1,041.42. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $12,889.99 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award to the pharmaceutical distributor and represents a continuation of the company's ongoing supply relationship with DLA. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of REPATHA 140 mg/mL SureClick auto-injectors with a ceiling value of $48,141.39. This competitively awarded, firm fixed price delivery order is not set-aside and has an ultimate completion date of August 20, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,964.30 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by July 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location in the same city. REPATHA is a prescription...
- The Defense Logistics Agency awarded a delivery order valued at $6,614.91 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 29, 2025. This non-set-aside, firm fixed price contract was competitively awarded on July 28, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,393.01 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 MG/ML SureClick auto-injectors. The contract, awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, represents a firm fixed price delivery order with no set-aside designation. This award was made under a competitive procurement process, reflecting AmerisourceBergen's capability to meet federal pharmaceutical supply requirements....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with a ceiling value of $1,041.42. This competitively awarded, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. REPATHA is a prescription medication used to treat high cholesterol and reduce...
- The Defense Logistics Agency awarded a delivery order valued at $6,293.41 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injector pharmaceutical product. The contract, executed on August 7, 2025, with completion targeted for August 8, 2025, utilized firm fixed-price pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB25FBRQCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $55,027.37 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 21, 2025. This firm fixed-price contract, awarded on August 20, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's $999,999,999.00 Pharmaceutical Prime Vendor Global Program IDC with DLA Troop Support Medical, designated as SPE2DX and running through December 2026. As a major pharmaceutical distributor and critical federal medical supply vendor, AmerisourceBergen serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through this comprehensive contract vehicle. REPATHA is a PCSK9 inhibitor used for cholesterol management and cardiovascular risk reduction, supporting military and veteran healthcare program needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $55.0k | 8/20/25 |